Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MetaVia Reports Positive Phase 1 DA-1726 Data for Weight Loss And Safety
Details : DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Product Name : DA-1726
Product Type : Peptide
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DA-1241,Sitagliptin Phosphate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MetaVia Announces Positive Phase 2a Results for DA-1241 in Presumed MASH Patients
Details : ASC47 is an adipose-targeted THRβ selective small molecule agonist. It is being evaluated in combination with semaglutide for the treatment of obesity.
Product Name : DA-1241
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : DA-1241,Sitagliptin Phosphate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable